PAVmed Appoints Shaun O’Neil as Chief Operating Officer
24 Februar 2022 - 2:25PM
Business Wire
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or
“PAVmed”), a diversified commercial-stage medical technology
company and parent of cancer prevention company Lucid
Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”), today announced the
appointment of Shaun O’Neil to serve as Executive Vice President
and Chief Operating Officer, overseeing diverse corporate
operations and commercial activities across the Company and its
subsidiaries. Mr. O’Neil has served as PAVmed’s Chief Commercial
Officer and Executive Vice President, Business Development since
joining the Company in 2018. He will serve on the Company’s
Executive Committee and as an executive officer pursuant to Section
16(a) of the Securities Exchange Act of 1934.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220224005446/en/
PAVmed appoints Shaun O’Neil as Chief
Operating Officer. (Photo: Business Wire)
“Mr. O’Neil has been an invaluable member of our company and its
leadership team since joining us nearly four years ago, including
playing a central role in our transition to a commercial
enterprise,” said Lishan Aklog M.D., PAVmed’s Chairman and Chief
Executive Officer. “He has built a solid and rapidly expanding
commercial infrastructure—including sales, marketing, and market
access—most notably for Lucid and its products, as well as nascent
commercial teams for other commercial and near-commercial products.
He has also played important roles in numerous other critical
corporate initiatives, including the launch of our Lucid Test
Center network, our transition to a dedicated CLIA-certified
laboratory and in various business development activities. His deep
involvement in operational and commercial activities across the
breadth of the company make him the ideal candidate to serve as our
inaugural COO, a position launched to accommodate our rapid growth
to nearly one hundred employees over the past year.”
“I am energized to take on this expanded role at such an
exciting time for PAVmed and its subsidiaries,” said Mr. O’Neil.
“We are in as strong a position as ever to execute on our strategic
plan, drive commercialization of our products and grow long-term
shareholder value. That strength is built on a solid balance sheet,
groundbreaking technologies, and the best team in the industry. I
look forward helping execute on our vision to transform PAVmed into
a leading global medical technology company.”
Mr. O’Neil has served as PAVmed’s Chief Commercial Officer and
Executive Vice President, Business Development since 2018. Prior to
PAVmed, Mr. O’Neil brought to PAVmed more than fifteen years of
sales and marketing leadership, and product and business
development expertise in both startup and established companies,
including a particularly strong track record in growing sales and
increasing market share for innovative medical devices. From 2011
to 2018 Mr. O’Neil held various sales and marketing leadership
positions with AngioDynamics (Nasdaq: ANGO), a leading provider of
innovative medical devices used by interventional radiologists,
interventional cardiologists, surgeons, and other physicians for
the minimally invasive diagnosis and treatment of cancer and
peripheral vascular disease. Prior to AngioDynamics, he served in
various sales, marketing and engineering roles at Aycan Medical
Systems, a privately held medical imaging company, Harris
Interactive and Quality Solutions Group. Mr. O’Neil received a
bachelor’s degree in Business Administration from Alfred University
and an M.B.A. from the Rochester Institute of Technology.
About PAVmed
PAVmed Inc. is a diversified commercial-stage medical technology
company operating in the medical device, diagnostics and digital
health sectors. Its major subsidiary, Lucid Diagnostics Inc.
(Nasdaq: LUCD), markets the EsoGuard® Esophageal DNA Test and
EsoCheck® Esophageal Cell Collection Device—the first and only
commercial tools for widespread early detection of esophageal
precancer to prevent esophageal cancer deaths. Another major
subsidiary, Veris Health Inc., is a digital health company
developing the first intelligent implantable vascular access port
with biologic sensors and wireless communication to improve
personalized cancer care through remote patient monitoring.
PAVmed’s CarpX® Minimally Invasive Device for Carpal Tunnel
Syndrome is currently in limited commercial release. The product
pipeline also includes the EsoCure™ Esophageal Ablation Device with
Caldus™ Technology, which complements EsoGuard and EsoCheck, the
NextFlo™ Intravenous Infusion Set, the PortIO™ Implantable
Intraosseous Vascular Access Device, novel pediatric ear tubes,
mechanical circulatory support technology and glucose monitoring.
For more information, please visit www.pavmed.com, follow us on
Twitter, connect with us on LinkedIn, and watch our videos on
YouTube. For more information on our majority owned subsidiary,
Lucid Diagnostics Inc., please visit www.luciddx.com, follow Lucid
on Twitter, and connect with Lucid on LinkedIn. For detailed
information on EsoGuard, please visit www.EsoGuard.com and follow
us on Twitter, Facebook and Instagram.
Forward-Looking Statements
This press release includes forward-looking statements that
involve risk and uncertainties. Forward-looking statements are any
statements that are not historical facts. Such forward-looking
statements, which are based upon the current beliefs and
expectations of PAVmed’s management, are subject to risks and
uncertainties, which could cause actual results to differ from the
forward-looking statements. Risks and uncertainties that may cause
such differences include, among other things, volatility in the
price of PAVmed’s common stock; PAVmed’s Series W and Series Z
warrants; general economic and market conditions; the uncertainties
inherent in research and development, including the cost and time
required to advance PAVmed’s products to regulatory submission;
whether regulatory authorities will be satisfied with the design of
and results from PAVmed’s clinical and preclinical studies; whether
and when PAVmed’s products are cleared by regulatory authorities;
market acceptance of PAVmed’s and products once cleared and
commercialized; PAVmed’s ability to raise additional funding as
needed; and other competitive developments. In addition, PAVmed has
been monitoring the COVID-19 pandemic and the pandemic’s impact on
PAVmed’s businesses. PAVmed expects the significance of the
COVID-19 pandemic, including the extent of its effect on its
financial and operational results, to be dictated by, among other
things, the success of efforts to contain the pandemic and the
impact of such efforts on PAVmed’s businesses. These factors are
difficult or impossible to predict accurately and many of them are
beyond PAVmed’s control. In addition, new risks and uncertainties
may arise from time to time and are difficult to predict. For a
further list and description of these and other important risks and
uncertainties that may affect PAVmed’s future operations, see Part
I, Item IA, “Risk Factors,” in PAVmed’s most recent Annual Report
on Form 10-K filed with the Securities and Exchange Commission, as
the same may be updated in Part II, Item 1A, “Risk Factors” in any
Quarterly Report on Form 10-Q filed by PAVmed after its most recent
Annual Report filed with the Securities and Exchange Commission.
PAVmed disclaims any intention or obligation to publicly update or
revise any forward-looking statement to reflect any change in its
expectations or in events, conditions, or circumstances on which
those expectations may be based, or that may affect the likelihood
that actual results will differ from those contained in the
forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220224005446/en/
Investors Adrian K. Miller PAVmed
Inc. AKM@PAVmed.com
Media Shani Lewis
LaVoieHealthScience (609) 516-5761
PAVmed@lavoiehealthscience.com
PAVmed (NASDAQ:PAVMZ)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
PAVmed (NASDAQ:PAVMZ)
Historical Stock Chart
Von Apr 2023 bis Apr 2024